Literature DB >> 19521246

Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis.

Dorien H Nieman1, Wera H Rike, Hiske E Becker, Peter M Dingemans, Thérèse A van Amelsvoort, Lieuwe de Haan, Mark van der Gaag, Damiaan A J P Denys, Don H Linszen.   

Abstract

Little is known about medication prescription in a naturalistic setting to patients at ultra high risk (UHR) of developing psychosis. Antipsychotic medication prescription to UHR patients is not recommended in clinical practice guidelines based on the current evidence. The aim of this study is to investigate medication prescription to UHR patients in the Netherlands. The frequency of antipsychotic medication prescription to UHR patients (n=72) was compared with the frequency of antipsychotic medication prescription to patients who were diagnosed with a Diagnostic and Statistical Manual of Mental Disorders, fourth edition psychotic disorder at first diagnostic evaluation (n=90). Within the UHR group, frequency of antipsychotic medication prescription at baseline was compared between UHR patients who did make the transition to psychosis (n=18) and UHR patients who did not (n=54). No significant differences were found in antipsychotic medication prescription to UHR patients and to patients who turned out to have a florid psychosis: 51% in the psychotic group and 58% in the UHR group used no medication. Thirty-four percent in the psychotic group and 21% in the UHR group used antipsychotic medication. There was also no difference in medication prescription between UHR patients who did and did not make the transition to psychosis. More research should be aimed at developing and implementing clinical practice guidelines for the treatment of UHR patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19521246     DOI: 10.1097/YIC.0b013e32832e0a76

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  6 in total

1.  The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population.

Authors:  Helga K Ising; Wim Veling; Rachel L Loewy; Marleen W Rietveld; Judith Rietdijk; Sara Dragt; Rianne M C Klaassen; Dorien H Nieman; Lex Wunderink; Don H Linszen; Mark van der Gaag
Journal:  Schizophr Bull       Date:  2012-04-19       Impact factor: 9.306

Review 2.  Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders.

Authors:  Molly K Larson; Elaine F Walker; Michael T Compton
Journal:  Expert Rev Neurother       Date:  2010-08       Impact factor: 4.618

3.  A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial.

Authors:  Judith Rietdijk; Sara Dragt; Rianne Klaassen; Helga Ising; Dorien Nieman; Lex Wunderink; Philippe Delespaul; Pim Cuijpers; Don Linszen; Mark van der Gaag
Journal:  Trials       Date:  2010-03-22       Impact factor: 2.279

4.  Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables.

Authors:  Dorien H Nieman; Stephan Ruhrmann; Sara Dragt; Francesca Soen; Mirjam J van Tricht; Johannes H T M Koelman; Lo J Bour; Eva Velthorst; Hiske E Becker; Mark Weiser; Don H Linszen; Lieuwe de Haan
Journal:  Schizophr Bull       Date:  2013-10-18       Impact factor: 9.306

5.  Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis.

Authors:  Aaltsje Malda; Nynke Boonstra; Hans Barf; Steven de Jong; Andre Aleman; Jean Addington; Marita Pruessner; Dorien Nieman; Lieuwe de Haan; Anthony Morrison; Anita Riecher-Rössler; Erich Studerus; Stephan Ruhrmann; Frauke Schultze-Lutter; Suk Kyoon An; Shinsuke Koike; Kiyoto Kasai; Barnaby Nelson; Patrick McGorry; Stephen Wood; Ashleigh Lin; Alison Y Yung; Magdalena Kotlicka-Antczak; Marco Armando; Stefano Vicari; Masahiro Katsura; Kazunori Matsumoto; Sarah Durston; Tim Ziermans; Lex Wunderink; Helga Ising; Mark van der Gaag; Paolo Fusar-Poli; Gerdina Hendrika Maria Pijnenborg
Journal:  Front Psychiatry       Date:  2019-05-21       Impact factor: 4.157

6.  Neurophysiological differences between patients clinically at high risk for schizophrenia and neurotypical controls--first steps in development of a biomarker.

Authors:  Frank H Duffy; Eugene D'Angelo; Alexander Rotenberg; Joseph Gonzalez-Heydrich
Journal:  BMC Med       Date:  2015-11-02       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.